Fexofenadine Hydrochloride Market Outlook 2029: Presents Market Insights & Depth Analysis

Fexofenadine hydrochloride market is expected to grow at a significant CAGR during the forecast period. Fexofenadine is an antihistamine pharmaceutical medicine used to treat allergy symptoms such as hay fever and urticaria. It is available under the trade names Allegra and others. Fexofenadine is a selective peripheral H1 blocker that can be used therapeutically. It is classed as a second-generation antihistamine as it is less likely than first-generation antihistamines to cross the blood–brain barrier and cause drowsiness.

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in July 2019, Dr. Reddy’s Laboratories Ltd. announced the launch of Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D 12 HR (USFDA). The following are the ingredients in Dr. Reddy’s OTC Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP: For temporary alleviation of symptoms such as runny nose, sneezing, itchy, watery eyes, and itching of the nose or throat caused by hay fever or other upper respiratory allergies. Nasal congestion caused by the common cold, hay fever, or other upper respiratory allergens can be temporarily relieved with this product. nasal passages to be less swollen. For the most recent twelve months ending in May 2019, the Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets brand and generic had US sales of roughly $44 million MAT. The 20- and 30-count quantities of Dr. Reddy’s OTC Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP are available.

To Request a Sample of our Report on Fexofenadine Hydrochloride Market:   https://www.omrglobal.com/request-sample/fexofenadine-hydrochloride-market

Market Coverage

  • The market number available for – 2022-2030
  • Base year- 2022
  • Forecast period- 2023-2030

Segment Covered- 

  • By Product
  • By Application

Regions covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape:  Sanofi S.A., Sandoz Inc. (Novartis International AG, and Dr. Reddy’s Laboratories Ltd., among others.

Fexofenadine Hydrochloride Market Report by Segment

By Type 

  • Purity:98%
  • Purity:>98%

By Application

  • Seasonal Allergic Rhinitis
  • Urticaria

A full Report of Fexofenadine Hydrochloride Market is Available @  https://www.omrglobal.com/industry-reports/fexofenadine-hydrochloride-market

Fexofenadine Hydrochloride Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe

Asia-Pacific

  • India
  • China
  • Japan
  • South Korea
  • Rest of APAC

Rest of the World

  • Latin America
  • Middle East & Africa

Reasons to buy from us –

  1. We cover more than 15 major industries, further segmented into more than 90 sectors.
  2. More than 120 countries are for analysis.
  3. Over 100+ paid data sources mined for investigation.
  4. Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404